Scarica l'app Stockscreener
1.88
3.30%
0.06
Sutro Biopharma Inc Borsa (STRO) Ultime notizie
Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Charles Schwab Investment Management Inc. Acquires 35,167 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma stock hits 52-week low at $2.02 By Investing.com - Investing.com Canada
Fmr LLC Acquires 37,701 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
BNP Paribas Financial Markets Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Novavax (NASDAQ:NVAX) and Sutro Biopharma (NASDAQ:STRO) Financial Review - Defense World
Sutro Biopharma's SWOT analysis: promising pipeline drives stock outlook - Investing.com
Sutro Biopharma’s (STRO) Outperform Rating Reiterated at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Earns “Market Outperform” Rating from JMP Securities - Defense World
Wells Fargo & Company Lowers Sutro Biopharma (NASDAQ:STRO) Price Target to $4.00 - Defense World
Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts - Benzinga
Sutro Biopharma stock hits 52-week low at $2.45 - Investing.com India
Sutro Biopharma stock hits 52-week low at $2.45 By Investing.com - Investing.com Canada
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer - The Manila Times
Sutro's Luvelta Shows Promising 32% Response Rate in Ovarian Cancer Trial, Eyes FDA Fast Track - StockTitan
Intech Investment Management LLC Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Point72 Asset Management L.P. Decreases Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Jacobs Levy Equity Management Inc. Lowers Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Bank of Montreal Can Makes New Investment in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (FRA:S09) Price-to-Operating-Cash-Flow : (As of Dec. 04, 2024) - GuruFocus.com
Sutro Biopharma (FRA:S09) Enterprise Value : €-129.3 Mil (As of Dec. 04, 2024) - GuruFocus.com
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Price Target at $12.14 - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Sees Large Drop in Short Interest - MarketBeat
Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge - Simply Wall St
Suvretta Capital Management LLC Sells 521,195 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Analysts Set Sutro Biopharma, Inc. (NASDAQ:STRO) Target Price at $12.14 - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $1.51 Million in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
Sutro Biopharma (STU:S09) Enterprise Value : €-142.7 Mil (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma (STU:S09) Forward Dividend Yield % : 0.00% (As of Nov. 27, 2024) - GuruFocus.com
Sutro Biopharma (STU:S09) Pre-Tax Income : €-99.1 Mil (TTM As of Sep. 2024) - GuruFocus.com
Sutro Biopharma's SWOT analysis: stock outlook amid clinical progress - Investing.com
Sutro Biopharma's SWOT analysis: stock outlook amid clinical progress By Investing.com - Investing.com Nigeria
Sutro Biopharma Advances Pipeline Amid Financial Losses - MSN
HC Wainwright Estimates Sutro Biopharma Q2 Earnings - Defense World
HC Wainwright Raises Earnings Estimates for Sutro Biopharma - Defense World
FY2024 EPS Forecast for Sutro Biopharma Boosted by Analyst - MarketBeat
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know - MSN
HC Wainwright Reaffirms Buy Rating for Sutro Biopharma (NASDAQ:STRO) - Defense World
HC Wainwright Weighs in on Sutro Biopharma Q2 Earnings - MarketBeat
Sutro Biopharma's (STRO) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Sutro Biopharma Through 5 Analysts - Benzinga
FY2024 EPS Estimates for Sutro Biopharma Lifted by Analyst - MarketBeat
Sutro Biopharma FY2024 EPS Forecast Increased by Wedbush - Defense World
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co. - MarketBeat
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates - MSN
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma earnings beat by $0.14, revenue fell short of estimates - Investing.com UK
Sutro Biopharma Inc (STRO) Q3 2024 Earnings: Revenue Misses Esti - GuruFocus.com
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sutro Biopharma Reports 56% Response Rate in Cancer Trial, Plans 3 New Drug Applications | STRO Stock News - StockTitan
BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):